TARO logo

Taro Pharmaceutical Industries (TARO) Stock

Profile

Sector:

Healthcare

Industry:

Drug Manufacturers - Specialty & Generic

Country:

Israel

IPO:

14 September 1982

Indexes:

Not included

Website:

http://www.taro.com

Description:

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Key Details

Price

-

Market Cap

-

Last Dividend

$12.81

TTM Dividend Yield

-

Annual Revenue

$629.18 M(+9.81% YoY)

Annual EPS

$1.43(+110.29% YoY)

PE Ratio

-

Annual ROE

3.06%

Annual Debt To Equity

0.00

Beta

-

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

July 26, 2024

Recent annual earnings:

May 20, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Dec 10, 2018
Splits

Next split:

N/A

Recent split:

July 27, 2001

Analyst ratings

Recent major analysts updates

18 Jan '24 HC Wainwright & Co.
Neutral
25 Jan '23 HC Wainwright & Co.
Buy
15 Aug '22 HC Wainwright & Co.
Buy
31 Jan '22 HC Wainwright & Co.
Buy
18 Jan '22 HC Wainwright& Co.
Buy
18 Jan '22 HC Wainwright & Co.
Buy
28 July '21 HC Wainwright & Co.
Buy
02 June '21 HC Wainwright & Co.
Buy
01 Feb '21 HC Wainwright & Co.
Buy
23 Nov '20 HC Wainwright & Co.
Buy

Screeners with TARO included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price All-time High

$171.77
TARO price is currently at an all-time high

Price Analysts Target

$43.00
TARO price is currently equal to the consensus analysts' forecast

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Last Paid Dividend

$12.81
TARO dividend per share is $12.81

Annual FCF

$70.34 M
TARO annual free cash flow is $70.34 million

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Revenue 3-Year Change

+14.61%
TARO annual revenue is up +14.61% over the past 3 years

Annual Net Income 3-Year Change

+113.93%
TARO annual net profit is up +113.93% over the past 3 years

Annual EPS 3-Year Change

+114.13%
TARO annual earnings per share is up +114.13% over the past 3 years

Annual Gross Profit

$304.96 M
TARO annual gross profit is $304.96 million

Annual Operating Profit

$21.48 M
TARO annual operaing income is $21.48 million

Annual Operating Profit 3-Year Change

-85.2%
TARO annual operaing income is down -85.2% over the past 3 years

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual ROE

3.06%
TARO annual return on equity is 3.06%

Annual ROA

2.51%
TARO annual return on assets is 2.51%

Annual EBIT

$21.48 M
TARO annual earnings before interest & taxes is $21.48 million

Annual EBITDA

$52.58 M
TARO annual earnings before interest, taxes, depreciation & amortization is $52.58 million

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual Quick Ratio

3.04
TARO annual quick ratio is 3.04

Annual Current Ratio

3.61
TARO annual current ratio is 3.61

Annual Total Assets

$2.16 B
TARO annual total assets is $2.16 billion

Annual Current Assets

$1.30 B
TARO annual total current assets is $1.30 billion

Annual Total Liabilities

$369.06 M
TARO annual total liabilities is $369.06 million

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Annual CFO 3-Year Change

+172.13%
TARO annual cash flow from operations is up +172.13% over the past 3 years

Annual CFI 3-Year Change

+24.51%
TARO annual cash flow from investing activities is up +24.51% over the past 3 years

Annual CAPEX

$54.22 M
TARO annual capital expenditures is $54.22 million

Annual CAPEX 3-Year Change

+216.1%
TARO annual capital expenditures is up +216.1% over the past 3 years

Annual FCF

$70.34 M
TARO annual free cash flow is $70.34 million

Annual FCF 3-Year Change

+145.78%
TARO annual free cash flow is up +145.78% over the past 3 years

Institutional Ownership

Similar stocks

FINAL TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Taro Pharmaceutical Industries Ltd. Investors to Join the Class Action Lawsuit!
FINAL TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Taro Pharmaceutical Industries Ltd. Investors to Join the Class Action Lawsuit!
FINAL TARO DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Taro Pharmaceutical Industries Ltd. Investors to Join the Class Action Lawsuit!
TARO
accesswire.com11 November 2024

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO
globenewswire.com10 November 2024

NEW YORK, Nov. 10, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (“Taro” or “the Company”) (NYSE: TARO) and certain of its officers.

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
TARO
accesswire.com10 November 2024

NEW YORK, NY / ACCESSWIRE / November 10, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Taro Pharmaceutical Industries Ltd. to Contact the Firm Today!
TARO
accesswire.com08 November 2024

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO
globenewswire.com04 November 2024

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. (“Taro” or “the Company”) (NYSE: TARO) and certain of its officers.

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!
TARO
accesswire.com03 November 2024

NEW YORK, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors Have Opportunity to Lead Class Action Lawsuit!
TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors Have Opportunity to Lead Class Action Lawsuit!
TARO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors Have Opportunity to Lead Class Action Lawsuit!
TARO
accesswire.com01 November 2024

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO
accesswire.com27 October 2024

NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO Investors Have Opportunity to Lead Taro Pharmaceutical Industries Ltd. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
TARO Investors Have Opportunity to Lead Taro Pharmaceutical Industries Ltd. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
TARO Investors Have Opportunity to Lead Taro Pharmaceutical Industries Ltd. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
TARO
accesswire.com23 October 2024

NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Taro Pharmaceutical Industries Ltd. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
TARO
accesswire.com20 October 2024

NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Taro Pharmaceutical Industries Ltd. ("Taro" or "the Company") (NYSE:TARO) and certain of its officers.

FAQ

  • What is the primary business of Taro Pharmaceutical Industries?
  • What is the ticker symbol for Taro Pharmaceutical Industries?
  • Does Taro Pharmaceutical Industries pay dividends?
  • What sector is Taro Pharmaceutical Industries in?
  • What industry is Taro Pharmaceutical Industries in?
  • What country is Taro Pharmaceutical Industries based in?
  • When did Taro Pharmaceutical Industries go public?
  • Is Taro Pharmaceutical Industries in the S&P 500?
  • Is Taro Pharmaceutical Industries in the NASDAQ 100?
  • Is Taro Pharmaceutical Industries in the Dow Jones?
  • When was Taro Pharmaceutical Industries's last earnings report?
  • When does Taro Pharmaceutical Industries report earnings?
  • Should I buy Taro Pharmaceutical Industries stock now?

What is the primary business of Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

What is the ticker symbol for Taro Pharmaceutical Industries?

The ticker symbol for Taro Pharmaceutical Industries is NYSE:TARO

Does Taro Pharmaceutical Industries pay dividends?

No, Taro Pharmaceutical Industries does not pay dividends

What sector is Taro Pharmaceutical Industries in?

Taro Pharmaceutical Industries is in the Healthcare sector

What industry is Taro Pharmaceutical Industries in?

Taro Pharmaceutical Industries is in the Drug Manufacturers - Specialty & Generic industry

What country is Taro Pharmaceutical Industries based in?

Taro Pharmaceutical Industries is headquartered in Israel

When did Taro Pharmaceutical Industries go public?

Taro Pharmaceutical Industries's initial public offering (IPO) was on 14 September 1982

Is Taro Pharmaceutical Industries in the S&P 500?

No, Taro Pharmaceutical Industries is not included in the S&P 500 index

Is Taro Pharmaceutical Industries in the NASDAQ 100?

No, Taro Pharmaceutical Industries is not included in the NASDAQ 100 index

Is Taro Pharmaceutical Industries in the Dow Jones?

No, Taro Pharmaceutical Industries is not included in the Dow Jones index

When was Taro Pharmaceutical Industries's last earnings report?

Taro Pharmaceutical Industries's most recent earnings report was on 26 July 2024

When does Taro Pharmaceutical Industries report earnings?

The date for Taro Pharmaceutical Industries's next earnings report has not been announced yet

Should I buy Taro Pharmaceutical Industries stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions